Retention rate in a longitudinal cannabis survey: Lessons for future studies

Juan G Perez-Carreno¹, Sophie Maloney¹, Hanzhi Gao², Ruba Sajdeya¹, Yan Wang¹, Robert L Cook¹, Catalina Lopez-Quintero¹.

University of Florida, Gainesville, Florida

- 1. Department of Epidemiology
- 2. Department of Biostatistics

BACKGROUND

- Longitudinal studies have found attrition to surveys up to 30%. The retention rate will typically decrease over time and change according to the survey modality (mail, phone, online, social media).
- Some studies report that incentives, such as \$10 gift cards, increase retention to follow-up. Additionally, cannabis cessation, reported in 16.3% of current or former cannabis users, can be associated with attrition.
- Associations between participant's characteristics with loss to follow-up status remain underreported and poorly understood.

AIM

To describe retention rates in a cannabis longitudinal study and characterize the population lost to follow-up in terms of socio-demographics, reasons for cannabis use, and cannabis use patterns.

METHODS

- 1. We analyzed data from the Medical Marijuana and Me study (M3), which included a longitudinal survey to characterize a population of new medical marijuana users in Florida.
- 2. Follow-up methods included mail, email reminders, and phone calls (3 maximum attempts per participant). The study offered a \$20 card plus a \$10-\$20 bonus for completing the follow-up survey within a week.
- 3. We described participant retention rates using the top three reasons for cannabis use.
- 4. Using bivariate analysis, we compared sociodemographics, standardized self-reported measures (Generalized Anxiety Disorder-7 scale; Patient Health Questionnaire Depression scale, and Cannabis Use Disorder Test-Revised: CUDIT-R), and cannabis use patterns between participants completing only the baseline survey and those completing both, the baseline and the 3-month survey.

Table 1 Sociodemographic Characteristics (n=602)

Sample retained		
Yes (n=363)	No (n=239)	p-value
41.8 (14.2)	39.9 (15.9)	0.117
311 (85.7)	192 (80.3)	0.084
49 (13.5)	37 (15.5)	0.496
41 (11.3)	34 (14.2)	0.287
28 (7.7)	23 (9.6)	0.41
238 (65.6)	132 (55.2)	0.011
		0.004
79 (21.8)	85 (35.6)	
227 (62.5)	128 (53.6)	
57 (15.7)	26 (10.9)	
218 (60.2)	157 (66.0)	0.155
195 (53.7)	107 (44.8)	0.032
	Yes (n=363) 41.8 (14.2) 311 (85.7) 49 (13.5) 41 (11.3) 28 (7.7) 238 (65.6) 79 (21.8) 227 (62.5) 57 (15.7) 218 (60.2)	Yes (n=363) No (n=239) 41.8 (14.2) 39.9 (15.9) 311 (85.7) 192 (80.3) 49 (13.5) 37 (15.5) 41 (11.3) 34 (14.2) 28 (7.7) 23 (9.6) 238 (65.6) 132 (55.2) 79 (21.8) 85 (35.6) 57 (15.7) 26 (10.9) 218 (60.2) 157 (66.0)

Table 2. Cannabis Use Patterns (n=602)

Sample retained				
Yes (n=363)	No (n=239)	p-value		
on for cannabis u	ıse, n(%)			
224 (61.7)	152 (63.3)	0.639		
155 (42.7)	112 (46.9)	0.315		
117 (32.2)	67 (28.0)	0.274		
142 (39.1)	80 (33.5)	0.16		
128 (35.3)	77 (32.2)	0.441		
Type of Product, n(%)				
309 (85.1)	199 (83.3)	0.538		
228 (62.8)	156 (65.3)	0.539		
137 (37.7)	94 (39.3)	0.695		
65 (17.9)	45 (18.8)	0.775		
79 (21.8)	52 (21.8)	0.999		
66 (18.2)	51 (21.3)	0.338		
237 (65.3)	157 (65.7)	0.919		
Cannabis use experience (years of use), n(%)				
65 (17.9)	31 (13.0)	0.103		
133 (36.6)	80 (33.5)			
165 (45.5)	128 (53.6)			
Cannabis Use Disorder				
fied CUDIT-R), n	(%)			
157 (62.1)	97 (53.6)	0.003		
69 (27.3)	43 (23.8)			
27 (10.7)	41 (22.7)			
Type of Use, n(%)				
16 (6.3)	31 (17.0)	0.001		
86 (34.0)	63 (34.6)			
151 (59.7)	88 (48.4)			
	Yes (n=363) on for cannabis u 224 (61.7) 155 (42.7) 117 (32.2) 142 (39.1) 128 (35.3) e of Product, n(% 309 (85.1) 228 (62.8) 137 (37.7) 65 (17.9) 79 (21.8) 66 (18.2) 237 (65.3) experience (years 65 (17.9) 133 (36.6) 165 (45.5) nabis Use Disord fied CUDIT-R), n 157 (62.1) 69 (27.3) 27 (10.7) ype of Use, n(%) 16 (6.3)	Yes (n=363) (n=239) In for cannabis use, n(%) 224 (61.7) 152 (63.3) 155 (42.7) 112 (46.9) 117 (32.2) 67 (28.0) 142 (39.1) 80 (33.5) 128 (35.3) 77 (32.2) If of Product, n(%) 309 (85.1) 199 (83.3) 228 (62.8) 156 (65.3) 137 (37.7) 94 (39.3) 65 (17.9) 45 (18.8) 79 (21.8) 52 (21.8) 66 (18.2) 51 (21.3) 237 (65.3) 157 (65.7) In perience (years of use), n(%) 65 (17.9) 31 (13.0) 133 (36.6) 80 (33.5) 165 (45.5) 128 (53.6) Inabis Use Disorder Ified CUDIT-R), n(%) 157 (62.1) 97 (53.6) 69 (27.3) 43 (23.8) 27 (10.7) 41 (22.7) In perience (yee, n(%) 16 (6.3) 31 (17.0) 86 (34.0) 63 (34.6)		







RESULTS

- By the third month, 60.3% of the participants remained in the study.
- Female sex, college degree, and health insurance were associated with three-month retention (p<0.05).
- Having no risk for Cannabis Use Disorder (CUDIT-R) and using cannabis mainly for medical purposes were associated with a complete follow-up at 3 months (p<0.005).
- No other mental health or product characteristics were associated with three-month retention.

CONCLUSIONS

- In the M3 study, some characteristics informed the likelihood of being adherent to the study visits. This information will help researchers adjust sample size calculation and target specific subpopulations to increase study participation and reduce selection bias.
- The results identified a group of participants who should be retained based on individual characteristics.
- Further research will help in understanding adherence to study procedures in cannabis research. For instance, using qualitative designs to assess values and preferences among people using cannabis for recreational purposes.

ACKNOWLEDGEMENTS

 This study is sponsored by state funding to the Consortium for Medical Marijuana Clinical Outcomes Research.

SELECTED REFERENCES

- Young, A.F., Powers, J.R. and Bell, S.L., 2006. Attrition in longitudinal studies: who do you lose?. Australian and New Zealand journal of public health, 30(4), pp.353-361.
- Scott, C.K., 2004. A replicable model for achieving over 90% follow-up rates in longitudinal studies of substance abusers. *Drug and alcohol dependence*, 74(1), pp.21-36.
- Lucas, P., Boyd, S., Milloy, M.J. and Walsh, Z., 2021. The impact of non-medical cannabis legalization and other exposures on retention in longitudinal cannabis research: a survival analysis of a prospective study of Canadian medical cannabis patients. *Journal of Cannabis Research*, 3, pp.1-14.